Skip to main content

Table 1 Included studies of antiplatelet use in HD patients: Study design, treatments, intervention, bleeding events (A: Aspirin P: Placebo S: Sulfinpyrazone C: Control Cl: Clopidogrel A + Cl: Aspirin + Clopidogrel D: Dipyramidole A + D Aspirin + Dipyramidole)

From: The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis

StudyYearStudy designControl groupInterventionBleeding Bleeding eventstotalPeriods
(months)
Quality score
     Defined a prioriDefined as usedBleedings/patients (n/n)   
Harter
[13]
1979RCTPlaceboAspirin 160 mg odNoTransfusionsA: 5/19 P: 13/25445M
Kaegi
[14]
1975RCT crossoverPlaceboSulfinpyrazone 200 mg tidNoGI bleedingsS: 2/45 P: 1/45456M
Kaufman
[15]
2003RCTPlaceboAspirin 325 mg + Clopidogrel 75 mg dailyYesAs major, intermediate and minorA + Cl:44/104
P: 23/96
200~ 7H
Kobayashi
[16]
1980RCTPlaceboTiclopidine 100 mg bidNoMajor or serious bleedingT: 4/47 P: 3/531003H
Kooistra [17]1994RCT
crossover
PlaceboAspirin 30 mg odNoBleeding incidents not due to HDA:2/137 P:5/1371373M
Liu [18]2016Prospective
cohort
ControlAspirin 100 mg odYesIntracranial hemorrhage, major bleeding events (i.e. gastrointestinal bleeding)A: 14/152 C:36/254406606
Obialo
[19]
2003Prospective
cohort
ControlAspirin 325 mg odNoGI bleedingsA: 5/21 C: 0/3152~ 47
Sreedhara
[20](a)
1994RCTPlaceboDipyramidole 75 mg tidNoGI adverse eventsD: 5/29
P: 2/24
10772?L
Sreedhara
[20](b)
  PlaceboAspirin 325 mg daily  A: 3/26
P: 2/24
107  
Sreedhara
[20](c)
  PlaceboAspirin 325 mg daily + Dipyramidole 75 mg tid  A + D: 5/28
P: 2/24
107  
Tayebi
[21]
2018RCTPlaceboAspirin 80 mg daily + Dipyramidole 75 mg dailyNoMajor or serious bleedingA + D: 2/20
P: 0/20
4012H